EVT 101
Alternative Names: ENS 101; EVT101Latest Information Update: 05 Nov 2023
At a glance
- Originator Roche
- Developer Evotec SE
- Class Antidementias; Antiparkinsonians
- Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 24 Sep 2021 Discontinued - Phase-II for Major depressive disorder (Treatment-experienced) in USA (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in France (PO)